The Cleveland Clinic Foundation

Nicholas M Boulis

Helmuth Kotschi

Anthony Shawan

A spinal cannula for delivering a therapeutic agent to a spinal cord target includes proximal and distal end portions, a middle portion, and a deployable cannula member having distal and proximal end portions and a first lumen extending between the end portions. The spinal cannula includes a fluid delivery line operably connected to the proximal end portion of the deployable cannula member, and a fluid delivery line including a second lumen in fluid communication with the first lumen. The spinal cannula includes a support cannula proximally located from the deployable cannula member and securely connected to a portion of the fluid delivery line. Additionally, the spinal cannula includes a delivery cannula having distal and proximal end portions and a third lumen extending between the end portions for receiving the support cannula. The proximal end portion includes a locking mechanism for releasably engaging the proximal end portion of the support cannula.

Floating spinal cannula and method of use

A spinal platform for delivering a therapeutic agent to a spinal cord target includes a brace member for attachment to a plurality of bony structures surrounding at least a portion of the spinal cord target, a carriage member operatively coupled to and movable along the brace member, and a universal joint for adjusting the coronal or sagittal angle of a surgical instrument. The brace member includes at least one longitudinal rail and a plurality of attachment members. The plurality of attachment members is operably connected to the at least one longitudinal rail. The at least one longitudinal rail includes a proximal end portion, a distal end portion, and a middle portion extending between the proximal and distal end portions. The universal joint is seated within a portion of the carriage member and is capable of delivering the therapeutic agent to the spinal cord target.

Spinal platform and method for delivering a therapeutic agent to a spinal cord target

A method of producing in a cell in vivo aneurotoxin light chain peptide by delivering into the cell in vivo a nucleic acid construct. The nucleic acid construct comprises (a) a nucleic acid encoding aneurotoxin light chain peptide and (b) a regulatory sequence operably linked to the nucleic acid to allow expression of the nucleic acid. The expression of the nucleic acid produces theneurotoxin light chain peptide in the cell in vivo.

Growing community of inventors

Decatur, GA, United States of America

Nicholas M Boulis